Vaxart (VXRT) Stock Rockets On COVID-19 Vaccine Data

Vaxart VXRT Stock News

Stock & ETF Trading Signals
Vaxart Inc (NASDAQ: VXRT) is headed for the top in the market this morning, and for good reason. The company announced clinical data from an orally administered COVID-19 vaccine. Here’s what’s going on:

Check out Joshua’s investing portfolio here.

VXRT Stock Gains After COVID-19 Vaccine Shows Promise

In the press release, Vaxart announced additional results from its Hamster Challenge Study. The Study is a preclinical study of the company’s oral COVID-19 vaccine in hamster models.

The company said that it realized significant reduction in lung viral load of 405 logs in hamsters that received two oral vaccine doses, when compared to hamsters that had not received the vaccine at all. Moreover, the vaccine seems to be leading to an antibody response. VXRT said that serum IgG antibody titers were above 10,000 in hamsters that receive two oral doses.

Importantly, the oral vaccination performed as well as the intranasal vaccination with respect to key indicators including protection from weight loss, protection from increase in lung weight, viral load reduction, and induction of serum IgG antibodies. This data suggests that the vaccine provides mucosal protection.

In a statement, Andrei Floroiu, CEO at VXRT, had the following to offer:

These additional data provide further evidence supporting the efficacy potential of our oral COVID-19 vaccine candidate. In addition, we believe that our room-temperature-stable oral tablet vaccine would be a more convenient, more practical solution to the COVID-19 pandemic as compared to cold-chain dependent injectable vaccines.

This News Is Huge

Day Trading Lessons
The COVID-19 pandemic is still very much in swing in the United States and around the world. While Pfizer and BioNTech are likely to be the first to bring a vaccine to market, a single vaccine isn’t likely to solve the problem quickly enough. Moreover, vaccines don’t last forever. So, this positive news suggests that Vaxart will be part of a very large market for the long run as consumers will need COVID-19 vaccines regularly.

Moreover, VXRT has the potential to take a large share of this future market. After all, most consumers would rather swollow a pill than be given an injection. The less invassive nature of the company’s COVID-19 vaccine candidate suggests that if the vaccine is approved, it could become the number one choice among patients.

All in all, today’s announcement was a giant leap in the right direction for the company. As such, VXRT stock is one for the watch list.

Seriously, Joshua Rodriguez shares his portfolio positions with you, FREE! Click here!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts and gain access to Joshua’s investing portfolio!

Subscribe Now

All we need is your email address.

Click here to subscribe if reading on mobile.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.